Did the FDA Approve Semax? What the July 23–24, 2026 Advisory-Committee Vote Actually Did

No, the FDA did not approve Semax. On July 24, 2026 the FDA’s Pharmacy Compounding Advisory Committee — the outside panel that advises the agency, abbreviated PCAC — voted 8–5 to recommend that Semax be added to the 503A bulks list, which names the ingredients a state-licensed pharmacy may use when compounding for an individual patient.

Semax is a genuinely unusual case, because it is regulatory-approved in Russia and has been used there clinically for years. That is a real fact and it is also legally irrelevant in the United States: FDA does not recognise another country’s approval, and no American pharmacy gains authority from it. A committee recommendation is advice, formal rulemaking has not run, and Semax is an unapproved drug here today.

Semax is regulatory-approved in Russia for stroke and encephalopathy indications, and that single fact generates more confusion than anything else about this compound. People encounter a peptide with an approval history, real clinical use and a body of published research, and reasonably conclude it must be approved somewhere that counts for them.

It is not. FDA makes its own determinations and does not adopt another regulator’s. The evidence behind the Russian approvals is concentrated in Russian institutions and has largely not been independently replicated in Western randomised controlled trials, which is one reason it has never cleared the U.S. pathway. On our grading scale that places Semax in the human-pilot tier — real human data, not robustly established clinical outcomes.

Note the precision here: Russia specifically. Broader claims that Semax is "approved across Eastern Europe" circulate widely, and we do not have sourcing for them.

Semax is not named in the WADA Prohibited List 2026 or the 2026 Monitoring Program. A full read of both found no entry, which makes it the clean inverse of TB-500 and MOTS-c — both named, both prohibited at all times.

That is a meaningfully different position, and it should still be treated carefully rather than as a green light. WADA revises the list annually and can capture substances through analogue clauses without naming them individually. Any athlete subject to anti-doping rules should confirm current status through Global DRO or their anti-doping organisation before use, not infer it from an absence.

The uses FDA put before the committee for Semax were cerebral ischemia, migraine and trigeminal neuralgia — all neurological, and the only substance of the seven whose agenda sat entirely in one specialty. Semax itself derives from a fragment of ACTH, a pituitary hormone, which is an unusual origin among the compounds heard.

I am a board-certified neurologist, and I will say plainly what that background does and does not license. It lets me read the trial literature in this area critically. It does not let me tell you that Semax treats any of these conditions, because the committee made no such finding, FDA has made no such finding, and the Western replication that would support one has not happened. The vote was about whether a pharmacy may use the ingredient. That is all it was about.

A substance gets nominated for the 503A bulks list. FDA reviews it and may put it in front of the advisory committee. The committee hears the evidence and votes a recommendation, which is where Semaxis now — and that recommendation is non-binding. FDA then decides whether to act, and if it does, it must run formal rulemaking: a proposed rule, a public comment period, and a final rule. Only at the end of that does a substance actually appear on the list. Not one rung of that ladder is FDA approval.

A recommendation to add a substance to the 503A bulks list is a decision about pharmacy compounding eligibility. It is not FDA approval, which is a separate pathway in which a sponsor submits clinical evidence for a specific finished product.

It is also worth being precise about what this vote was not. These substances came off FDA’s 503A Category 2 list — the “significant safety risk” designation — back in April 2026, when their nominations were withdrawn, and that did not move them to Category 1. The July vote was a separate, later step: a recommendation to add them to a permission list. Coming off a restriction list in April and being recommended for a permission list in July are two different actions, months apart, and merging them into a single “ban lifted” story misstates both. The full sequence is on our FDA peptide compounding status page, and what has to happen next is laid out separately.

Nothing today. If a clinic or an online seller tells you the FDA just approved Semax, or that it is newly legal and you should act before the window closes, that is a sales pitch resting on a misreading of a procedural vote. The rules governing what a pharmacy may compound are the same this week as last week. You can check one piece of that yourself in about ten seconds: FDA’s own 503A category list still carries its May 14, 2026 update date, because these votes did not change it.

Anything sold to you in the meantime as “research use only” is not a prescription, is not dispensed by a licensed pharmacy, and carries no guarantee about what is actually in it. Given that FDA’s own chemists told the committee they could not always say what these compounds are, that is not an abstract concern. If you want the clinical picture for this substance rather than the regulatory one, see the Semax overview; for state law, see is peptide therapy legal in Nevada.